NCT05684289View on ClinicalTrials.gov

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

May 2, 2023

Study Completion Date

May 2, 2023

Conditions
Healthy Participants
Interventions
DRUG

BMS-986278

Specified dose on specified days

DRUG

Sildenafil

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (2)

33136

Syneos Health Clinical Research Services, Llc, Miami

90630

Altasciences Clinical Los Angeles, Inc, Cypress

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05684289 - A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2) | Biotech Hunter | Biotech Hunter